BSJ-5-63

• Description:

  BSJ-5-63 is a potent CDK12, CDK7, CDK9 PROTAC degrader. BSJ-5-63 BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9, RNAPII, Cyclin K. BSJ-5-63 decreases the mRNA expression of BRCA1, BRCA2. BSJ-5-63 shows anticancer activity and has the potential for the research of prostate cancer (Pink: ligand for target protein (HY-150948) ; black: linker (HY-W140827) ; Blue: E3 ligase ligand (HY-112078) ) [1].

• UNSPSC:

  12352211

• Target:

  CDK; PROTACs

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; PROTAC

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bsj-5-63.html

• Purity:

  99.97

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=S (C1=CC=CC=C1NC2=NC (N[C@H]3CN (CCCCCCCCCCC (N[C@@H] (C (C) (C) C) C (N4C[C@H] (O) C[C@H]4C (N[C@@H] (C) C5=CC=C (C6=C (C) N=CS6) C=C5) =O) =O) =O) CCC3) =NC=C2Cl) (C (C) C) =O

• Molecular Formula:

  C52H74ClN9O6S2

• Molecular Weight:

  1020.78

• References & Citations:

  [1]Gui F, et al. Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer. bioRxiv [Preprint]. 2024 Jul 10:2024.07.09.602803.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  Store at room temperature 3 years

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK12; CDK7; CDK9

• CAS Number:

  2519823-37-9